Patents by Inventor WenShing TSAO

WenShing TSAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9834561
    Abstract: The present invention provides efficient, economical, and improved methods for synthesizing ibrutinib and intermediates thereof. The invention involves a unique biphasic acylation reaction system which advantageously allows for easy separation of ibrutinib from the reaction mixture without additional extraction and wash steps. The isolated ibrutinib formed using the methods described herein can be useful in the preparation of an amorphous form of ibrutinib. In some embodiments, the isolated ibrutinib produced by the processes described herein is a homogenous solution of ibrutinib and DMSO which may be directly used in the formation of the amorphous polymorph. In some embodiments, the isolated ibrutinib is solid ibrutinib. The solid ibrutinib may also be used in the formation of amorphous ibrutinib.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: December 5, 2017
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Tsung-Yu Hsiao, MengFen Ho, HsinChang Tseng, WenShing Tsao, YuanChang Huang, Wei-Shuo Lo
  • Publication number: 20170145017
    Abstract: The present invention provides efficient, economical, and improved methods for synthesizing ibrutinib and intermediates thereof. The invention involves a unique biphasic acylation reaction system which advantageously allows for easy separation of ibrutinib from the reaction mixture without additional extraction and wash steps. The isolated ibrutinib formed using the methods described herein can be useful in the preparation of an amorphous form of ibrutinib. In some embodiments, the isolated ibrutinib produced by the processes described herein is a homogenous solution of ibrutinib and DMSO which may be directly used in the formation of the amorphous polymorph. In some embodiments, the isolated ibrutinib is solid ibrutinib. The solid ibrutinib may also be used in the formation of amorphous ibrutinib.
    Type: Application
    Filed: October 27, 2016
    Publication date: May 25, 2017
    Inventors: Tsung-Yu HSIAO, MengFen HO, HsinChang TSENG, WenShing TSAO, YuanChang HUANG, Wei-Shuo LO